Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral ... Seite 1

Related Keywords

United States ,San Francisco ,California ,American ,Himisha Beltran ,Drug Administration ,Nasdaq ,Md Dana Farber Cancer Institute ,Harpoon Therapeutics Inc ,Harpoon Therapeutics Abstract ,Rapid Oral Presentation ,Clinical Oncology Genitourinary Cancers Symposium ,American Society ,Activating Construct ,T Cell Engager ,Neuroendocrine Prostate Cancer ,Neuroendocrine Neoplasms ,Rapid Oral Abstract Session ,Prostate Cancer ,Dana Farber Cancer Institute ,Orphan Drug Designation ,Harpoon Therapeutics ,